-
Nobel winner Mukwege warns of predatory US deal for DR Congo
-
UK economy resilient as Mideast war, political risks loom
-
Russia pummels Kyiv, killing three and denting peace hopes
-
Subdued Trump left waiting for 'big hug' from Xi
-
Slot has 'every reason to believe' he will remain as Liverpool boss
-
British PM battles to stay in power amid rebellion
-
Ex-Philippine drug war enforcer flees Senate refuge
-
U2 surprise fans in Mexico City to shoot music video
-
Asia stocks uneven as investors assess high-stakes Trump-Xi talks, AI rally
-
Burberry returns to full-year profit on turnaround plan
-
Spiky, polarising, rarely dull: ups and downs of rugby's Eddie Jones
-
Denmark, Australia in the spotlight in Eurovision second semi
-
Heavy Russian strikes on Kyiv kill one, wound 31
-
Xi warns Trump on Taiwan at Beijing summit
-
Iran war and oil dominate BRICS meet in India
-
Bone appetit: Paris pups lap up treats at dog-centric spots
-
Kohli senses end after roaring back to form with IPL century
-
India bars sugar exports until September
-
Madonna, Shakira, BTS to headline first World Cup final half-time show
-
Japan takes 'half step' toward fixing slow retrial system
-
Honda posts operating loss, first since 1957
-
Madonna, Shakira, BTS to headline World Cup final half-time show
-
A quarter of World Cup games risk searing heat: scientists
-
Six hantavirus cruise passengers head to Australia
-
Suspect detained in Philippine senate gunfire: police
-
Cavs top Pistons in overtime for 3-2 series lead
-
Canadian football ready for World Cup coming out party
-
US court suspends sanctions on UN expert on Palestinians
-
Asia markets mixed as Trump-Xi summit, AI trade dominate
-
'Promised to us': The Israelis dreaming of settling south Lebanon
-
'Rare, meaningful': North Korean football team ventures into South
-
In-form Messi hits brace as Miami win 5-3 at Cincinnati in MLS
-
Historic Swiss solar-powered plane crashes into sea
-
A woman UN leader is 'historical justice,' says Ecuadoran contender for top job
-
Indian pharma fuels Africa's 'zombie drug' and opioid crisis
-
After months of blackout, Iran gives internet to select few
-
Wood urges New Zealand to 'create some history' at World Cup
-
In Washington, the fight to preserve Black cemeteries
-
US children's book author sentenced to life after poisoning husband
-
Emotional Vin Diesel leads 'Fast and Furious' tribute in Cannes
-
NAV Fund Services (Ireland) Ltd. Expands European Fund Servicing Offering to Support UCITS Funds
-
AVI Urges the Dismissal of Two Directors at Wacom
-
PLAS-LABS Simplifies Scientific Validation With Automated Citation Tracking Powered by Bioz
-
Battery X Metals Achieves Milestone with Delivery of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Machine Featuring Design Enhancements, Advancing Strategic Commercialization Initiatives
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - May 14
-
Akkodis Recognized in HFS Horizons 2026 Report for Enterprise Ready Agentic AI Services
-
Lexus Of Oakville Recognized for Redefining the Luxury Dealership Experience With 2026 Consumer Choice Award
-
US renews offer of $100 mn to Cuba if it cooperates
-
City still 'alive' but need Arsenal slip: Guardiola
-
Man City ease past Palace to keep pressure on Arsenal
Trump administration releases report critical of youth gender care
US President Donald Trump's administration on Thursday released what it described as a comprehensive review of gender interventions for children and adolescents, raising alarms about "significant risks" with puberty blockers and surgeries.
The 400-page report was published without named authors -- a decision that departs from standard scientific practice but was justified by the Department of Health and Human Services as a way "to help maintain the integrity of this process."
Gender care for youth is a deeply polarizing issue in many countries, with medical professionals striving to balance competing priorities: alleviating psychological distress, respecting patient autonomy, and ensuring that any interventions are safe, evidence-based, and appropriate for developing bodies and minds.
The Trump administration's well-documented hostility toward transgender people, and its frequent attacks on what it calls "woke gender ideology," have raised questions about the objectivity of the study.
According to the report, gender-affirming treatments pose risks "including infertility/sterility, sexual dysfunction, impaired bone density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret."
"Our duty is to protect our nation's children -- not expose them to unproven and irreversible medical interventions," Jay Bhattacharya, director of the National Institutes of Health. "We must follow the gold standard of science, not activist agendas."
But Aisha Mays, a family physician in California and member of the nonprofit Physicians for Reproductive Health, hit back by terming the report "propaganda."
"Today's report is propaganda aiming to delegitimize the perfectly safe, effective, and evidence-based health care that transgender people access to be who they are," she said.
"Being transgender, just like being cisgender, is not a choice nor can it be reversed by any medical or social method. The same way cisgender people know who they are, so do trans people. The same way cis people receive gender-affirming care, so do trans people."
In the UK, a separate high-profile review last year urged "extreme caution" when prescribing hormone treatments.
The four-year probe of child and youth gender identity services, led by retired pediatrician Hilary Cass, made dozens of recommendations ranging from more research to reform of the referrals system.
The American Academy of Pediatrics has maintained its support for providing transgender adolescents with medically necessary care and opposes legislation that restricts such access or interferes with the doctor-patient relationship.
While the political rhetoric around gender care has grown louder, data shows that in reality the use of such care is not widespread.
Fewer than 0.1 percent of gender-diverse minors with private insurance received puberty blockers or hormone therapy between 2018 and 2022, according to a recent study published in JAMA Pediatrics.
A.Williams--AT